# Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC

> **NCT03987867** · PHASE1 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer
- First-line Treatment

## Interventions

- **BIOLOGICAL:** CIK cell
- **BIOLOGICAL:** Sintilimab Injection
- **DRUG:** Pemetrexed
- **DRUG:** Liposome paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT03987867
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-01
- **Primary completion:** 2021-06-01
- **Final completion:** 2021-06-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03987867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03987867, "Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT03987867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*